Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.8.4203

Serum Oncofetal Fibronectin (onfFN) mRNA in Differentiated Thyroid Carcinoma (DTC): Large Overlap between Disease-Free and Metastatic Patients  

Sritara, Chanika (Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital)
Charoenphun, Putthiporn (Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital)
Ponglikitmongkol, Mathurose (Department of Biochemistry, Faculty of Science, Mahidol University)
Musikarat, Suchawadee (Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital)
Utamakul, Chirawat (Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital)
Chokesuwattanasakul, Payap (Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital)
Thakkinstian, Ammarin (Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.8, 2012 , pp. 4203-4208 More about this Journal
Abstract
Aim: This study assessed if onfFN mRNA in the peripheral blood of patients with DTC can identify individuals with metastatic disease. Methods: Comparison of onfFN mRNA was made among 3 groups: disease-free, lymph node metastasis, and distant metastasis using real-time RT-PCR on 5 ml blood samples from each DTC patient. Results: Fifty-one patients were included: 30 (59%) were disease-free; 7 (13.7%) had lymph node metastasis; and 14 (27.5%) had distant metastasis. OnfFN mRNA levels in the 3 groups were significantly different (P=0.001) but with a large overlap and the expression being highest in the disease-free group. Subgroup analysis of the metastatic groups did not show any effect of age, cell type, and serum TSH, Tg, and antiTg on onfFN mRNA. The within-run and between-run root mean square coefficients of variations were <2%. Conclusion: OnfFN mRNA in patients with DTC cannot identify those with metastatic disease.
Keywords
Oncofetal fibronectin; mRNA; real-time RT-PCR; differentiated thyroid carcinoma; metastasis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Schaadt B, Feldt-Rasmussen U, Rasmusson B, et al (1995). Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma. Thyroid, 5, 165-70.
2 Schmittgen T D, Lee E J, Jiang J (2008). High-throughput realtime PCR. Methods Mol Biol, 429, 89-98.   DOI
3 Schmittgen T D, Livak K J (2008). Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc, 3, 1101-8.   DOI
4 Spencer C A, Takeuchi M, Kazarosyan M, et al (1998). Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab, 83, 1121-7.   DOI   ScienceOn
5 Sritara C, Taeshineetanakul P, Kositwatanarerk A, et al (2008). Cutoff Point for Serum TgAb by ICMA Technique in Patients with Differentiated Thyroid Carcinoma (abstract). European Association of Nuclear Medicine, 35, 374.
6 Takano T, Matsuzuka F, Miyauchi A, et al (1998). Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study. Br J Cancer, 78, 221-4.   DOI
7 Takano T, Miyauchi A, Yokozawa T, et al (1999). Preoperative diagnosis of thyroid papillary and anaplastic carcinomas by real-time quantitative reverse transcription-polymerase chain reaction of oncofetal fibronectin messenger RNA. Cancer Res, 59, 4542-5.
8 Takano T, Miyauchi A, Matsuzuka F, Kuma K, Amino N (2000). Expression of oncofetal fibronectin messenger ribonucleic acid in fibroblasts in the thyroid: a possible cause of false positive results in molecular-based diagnosis of thyroid carcinomas. J Clin Endocrinol Metab, 85, 765-8.   DOI
9 Takano T, Ito Y, Matsuzuka F, et al (2007). Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma. Jpn J Clin Oncol, 37, 647-51.   DOI
10 Ward P, Poitras E, Leblanc D, et al (2009). Comparative analysis of different TaqMan real-time RT-PCR assays for the detection of swine Hepatitis E virus and integration of Feline calicivirus as internal control. J Appl Microbiol, 106, 1360-9.   DOI
11 Wehmeier M, Petrich T, Brand K, Lichtinghagen R, Hesse E (2010). Oncofetal fibronectin mRNA is highly abundant in the blood of patients with papillary thyroid carcinoma and correlates with high-serum thyroid-stimulating hormone levels. Thyroid, 20, 607-13.   DOI
12 Zanotti-Fregonara P, Keller I, Calzada-Nocaudie M, et al (2010). Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: are there sources of benign secretion? A speculative short review. Nucl Med Commun, 31, 1054-8.
13 Cooper D S, Doherty G M, Haugen B R, et al (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-214.   DOI   ScienceOn
14 Davies L, Welch H G (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, 295, 2164-7.   DOI   ScienceOn
15 Alzahrani A S, Raef H, Sultan A, et al (2002). Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer. J Endocrinol Invest, 25, 526-31.   DOI
16 Burgess J R, Tucker P (2006). Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid, 16, 47-53.   DOI
17 Chang J T, Chen I H, Liao C T, et al (2002). A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem, 35, 591-6.   DOI   ScienceOn
18 Chung J K, Park Y J, Kim T Y, et al (2002). Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf), 57, 215-21.   DOI   ScienceOn
19 Eustatia-Rutten C F, Smit J W, Romijn J A, et al (2004). Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf), 61, 61-74.   DOI
20 Ferrari L, Seregni E, Aliberti G, et al (2004). Comparative evaluation of two methods to assay thyroglobulin serum concentrations in patients with differentiated thyroid carcinomas. Q J Nucl Med Mol Imaging, 48, 237-42.
21 Hesse E, Musholt P B, Potter E, et al (2005). Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma. Br J Cancer, 93, 565-70.   DOI
22 Livak K J, Schmittgen T D (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8.   DOI   ScienceOn
23 Hjiyiannakis P, Mundy J, Harmer C (1999). Thyroglobulin antibodies in differentiated thyroid cancer. Clin Oncol (R Coll Radiol), 11, 240-4.   DOI
24 Hollowell J G, Staehling N W, Flanders W D, et al (2002). Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab, 87, 489-99.   DOI   ScienceOn
25 Leenhardt L, Grosclaude P, Cherie-Challine L (2004). Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid, 14, 1056-60.   DOI   ScienceOn
26 Pacini F, Schlumberger M, Dralle H, et al (2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154, 787-803.   DOI   ScienceOn
27 Rego-Iraeta A, Perez-Mendez L F, Mantinan B, Garcia-Mayor R V (2009). Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid, 19, 333-40.   DOI
28 Rosario P W, Maia F F, Fagundes T A, et al (2004). Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arq Bras Endocrinol Metabol, 48, 487-92.   DOI
29 Rubello D, Casara D, Girelli M E, Piccolo M, Busnardo B (1992). Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med, 33, 1478-80.